Galecto (GLTO) Competitors $3.01 +0.21 (+7.50%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. TXMD, GOVX, MBRX, TRIB, CLDI, CLRB, ABP, MRKR, NRSN, and MEShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include TherapeuticsMD (TXMD), GeoVax Labs (GOVX), Moleculin Biotech (MBRX), Trinity Biotech (TRIB), Calidi Biotherapeutics (CLDI), Cellectar Biosciences (CLRB), Abpro (ABP), Marker Therapeutics (MRKR), NeuroSense Therapeutics (NRSN), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry. Galecto vs. TherapeuticsMD GeoVax Labs Moleculin Biotech Trinity Biotech Calidi Biotherapeutics Cellectar Biosciences Abpro Marker Therapeutics NeuroSense Therapeutics 23andMe TherapeuticsMD (NASDAQ:TXMD) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk. Does the MarketBeat Community believe in TXMD or GLTO? TherapeuticsMD received 354 more outperform votes than Galecto when rated by MarketBeat users. However, 60.38% of users gave Galecto an outperform vote while only 58.13% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformTherapeuticsMDOutperform Votes38658.13% Underperform Votes27841.87% GalectoOutperform Votes3260.38% Underperform Votes2139.62% Do insiders and institutionals have more ownership in TXMD or GLTO? 30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 2.3% of TherapeuticsMD shares are held by company insiders. Comparatively, 11.9% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TXMD or GLTO? Galecto has a consensus price target of $10.00, indicating a potential upside of 257.14%. Given Galecto's stronger consensus rating and higher possible upside, analysts clearly believe Galecto is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, TXMD or GLTO? TherapeuticsMD has higher revenue and earnings than Galecto. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.76M8.15-$10.28MN/AN/AGalectoN/AN/A-$38.35M-$18.61-0.15 Is TXMD or GLTO more profitable? Galecto has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-207.77% -14.08% -9.61% Galecto N/A -76.96%-66.59% Which has more risk & volatility, TXMD or GLTO? TherapeuticsMD has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Does the media prefer TXMD or GLTO? In the previous week, TherapeuticsMD had 1 more articles in the media than Galecto. MarketBeat recorded 2 mentions for TherapeuticsMD and 1 mentions for Galecto. Galecto's average media sentiment score of 1.87 beat TherapeuticsMD's score of 0.94 indicating that Galecto is being referred to more favorably in the news media. Company Overall Sentiment TherapeuticsMD Positive Galecto Very Positive SummaryGalecto beats TherapeuticsMD on 8 of the 15 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.70M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.157.4422.4818.48Price / SalesN/A242.70395.93103.60Price / CashN/A65.8538.1834.62Price / Book0.096.516.774.25Net Income-$38.35M$143.21M$3.22B$248.23M7 Day Performance-1.75%1.98%1.47%0.89%1 Month Performance-0.71%6.89%3.99%3.53%1 Year Performance-83.54%-2.52%16.15%5.08% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.1169 of 5 stars$3.01+7.5%$10.00+232.2%-83.7%$3.97MN/A-0.1640Upcoming EarningsPositive NewsGap UpTXMDTherapeuticsMD1.7627 of 5 stars$1.22+6.1%N/A-34.0%$14.12M$1.76M0.00420Analyst ForecastGOVXGeoVax Labs2.7814 of 5 stars$1.02+4.4%$12.90+1,164.7%-27.9%$14.12M$3.95M-0.1810MBRXMoleculin Biotech2.9511 of 5 stars$0.99-6.9%$6.00+508.1%-78.9%$13.81MN/A0.0020Short Interest ↓News CoverageTRIBTrinity Biotech1.6645 of 5 stars$0.76+7.3%N/A-57.0%$13.72M$59.13M-0.34480Analyst ForecastShort Interest ↓Positive NewsGap UpCLDICalidi Biotherapeutics2.1673 of 5 stars$0.48-0.3%$15.00+3,014.0%N/A$13.71M$50,000.000.0038CLRBCellectar Biosciences1.7394 of 5 stars$0.30-4.4%$12.50+4,117.3%-91.9%$13.66MN/A-0.1710News CoverageGap UpABPAbproN/A$0.26-18.0%$4.00+1,434.3%N/A$13.61M$183,000.000.0015Gap UpHigh Trading VolumeMRKRMarker Therapeutics4.5598 of 5 stars$1.26+0.8%$13.17+945.0%-70.6%$13.49M$6.59M-1.0560Short Interest ↓NRSNNeuroSense Therapeutics1.1221 of 5 stars$0.98-2.1%N/A-27.4%$13.38MN/A-1.5310Short Interest ↓Negative NewsME23andMeN/A$0.50-35.3%N/A-95.0%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies TherapeuticsMD Competitors GeoVax Labs Competitors Moleculin Biotech Competitors Trinity Biotech Competitors Calidi Biotherapeutics Competitors Cellectar Biosciences Competitors Abpro Competitors Marker Therapeutics Competitors NeuroSense Therapeutics Competitors 23andMe Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLTO Stock Free GLTO Stock Alerts